Morgan Stanley
ABEO icon

Morgan Stanley’s Abeona Therapeutics ABEO Stock Holding History

Morgan Stanley’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.51M Sell
337,562
-136,099
-29% -$680K ﹤0.01% 4927
2025
Q4 		$2.5M Sell
473,661
-133,980
-22% -$674K ﹤0.01% 4655
2025
Q3 		$3.21M Sell
607,641
-361,635
-37% -$2.29M ﹤0.01% 4476
2025
Q2 		$5.51M Buy
969,276
+653,604
+207% +$3.72M ﹤0.01% 3985
2025
Q1 		$1.5M Buy
315,672
+184,771
+141% +$1M ﹤0.01% 4782
2024
Q4 		$729K Sell
130,901
-46,445
-26% -$286K ﹤0.01% 5245
2024
Q3 		$1.12M Sell
177,346
-418,652
-70% -$2.19M ﹤0.01% 4987
2024
Q2 		$2.53M Buy
595,998
+564,963
+1,820% +$2.88M ﹤0.01% 4402
2024
Q1 		$225K Sell
31,035
-627
-2% -$3.97K ﹤0.01% 5693
2023
Q4 		$159K Buy
31,662
+26,952
+572% +$119K ﹤0.01% 6028
2023
Q3 		$19.8K Hold
4,710
– – ﹤0.01% 6492
2023
Q2 		$19K Hold
4,710
– – ﹤0.01% 6585
2023
Q1 		$13.3K Sell
4,710
-4
-0.1% -$10 ﹤0.01% 6778
2022
Q4 		$14.5K Sell
4,714
-2
-0% -$7 ﹤0.01% 6805
2022
Q3 		$14K Sell
4,716
-1,998
-30% -$8.24K ﹤0.01% 6944
2022
Q2 		$35K Sell
6,714
-346
-5% -$1.75K ﹤0.01% 6765
2022
Q1 		$55K Sell
7,060
-127,818
-95% -$878K ﹤0.01% 6656
2021
Q4 		$1.14M Buy
134,878
+81,551
+153% +$1.5M ﹤0.01% 4979
2021
Q3 		$1.49M Sell
53,327
-19,281
-27% -$617K ﹤0.01% 4790
2021
Q2 		$2.83M Buy
72,608
+51,418
+243% +$2.1M ﹤0.01% 4343
2021
Q1 		$996K Buy
21,190
+13,961
+193% +$769K ﹤0.01% 4733
2020
Q4 		$283K Buy
7,229
+3,375
+88% +$115K ﹤0.01% 5407
2020
Q3 		$99K Sell
3,854
-1,970
-34% -$124K ﹤0.01% 5442
2020
Q2 		$425K Buy
5,824
+56
+1% +$3.87K ﹤0.01% 4682
2020
Q1 		$303K Sell
5,768
-178
-3% -$11.9K ﹤0.01% 4656
2019
Q4 		$486K Buy
5,946
+1,850
+45% +$131K ﹤0.01% 4936
2019
Q3 		$231K Buy
4,096
+1,629
+66% +$122K ﹤0.01% 5061
2019
Q2 		$294K Buy
2,467
+88
+4% +$14.8K ﹤0.01% 4855
2019
Q1 		$438K Sell
2,379
-440
-16% -$78.7K ﹤0.01% 4617
2018
Q4 		$504K Sell
2,819
-1,445
-34% -$315K ﹤0.01% 4781
2018
Q3 		$1.36M Sell
4,264
-4,735
-53% -$1.68M ﹤0.01% 4299
2018
Q2 		$3.6M Sell
8,999
-4,715
-34% -$2.06M ﹤0.01% 3537
2018
Q1 		$4.92M Sell
13,714
-2,152
-14% -$800K ﹤0.01% 3045
2017
Q4 		$6.29M Buy
15,866
+14,206
+856% +$5.87M ﹤0.01% 2844
2017
Q3 		$708K Buy
1,660
+209
+14% +$56.2K ﹤0.01% 4658
2017
Q2 		$232K Sell
1,451
-2,734
-65% -$373K ﹤0.01% 5258
2017
Q1 		$523K Buy
4,185
+4,027
+2,549% +$519K ﹤0.01% 4811
2016
Q4 		$19K Sell
158
-128
-45% -$20K ﹤0.01% 6014
2016
Q3 		$43K Buy
286
+33
+13% +$3.23K ﹤0.01% 5646
2016
Q2 		$15K Sell
253
-203
-45% -$13.9K ﹤0.01% 5936
2016
Q1 		$29K Sell
456
-10
-2% -$662 ﹤0.01% 5803
2015
Q4 		$39K Sell
466
-1,013
-68% -$102K ﹤0.01% 5796
2015
Q3 		$149K Sell
1,479
-3,353
-69% -$445K ﹤0.01% 5229
2015
Q2 		$611K Buy
4,832
+4,792
+11,980% +$720K ﹤0.01% 4564
2015
Q1 		$3K Buy
+40
New +$3.22K ﹤0.01% 6390

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley's ABEO Position: Q1 2026 in Review

Morgan Stanley reduced its Abeona Therapeutics (ABEO) stake by 29% in Q1 2026, selling an estimated $680K and leaving 337,562 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #4927.

Morgan Stanley first reported a position in ABEO in Q1 2015 and has held it in 45 quarters since. The position peaked at $6.29M in Q4 2017. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Morgan Stanley held 337,562 shares of Abeona Therapeutics worth $1.51M as of Q1 2026.
  • Morgan Stanley sold 136,099 Abeona Therapeutics shares in Q1 2026, an estimated $680K.
  • Abeona Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4927 holding.
  • Morgan Stanley first reported a position in Abeona Therapeutics in Q1 2015 and has held it in 45 quarters since.
  • Morgan Stanley's Abeona Therapeutics position peaked at $6.29M in Q4 2017.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.